Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer.

Trial Profile

Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2014

At a glance

  • Drugs Temsirolimus (Primary) ; Diphenhydramine; Diphenhydramine
  • Indications Prostate cancer
  • Focus Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Aug 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 04 Jun 2010 One patient had been enrolled by December 2009 according to information presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO-2010).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top